Physician profile
Tracy E Bullard
NPI 1255334736
$1,892.02
in general payments reported to CMS, 2019-2025
14 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.80 · 2022: $125 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $643.89 | 2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $563.79 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $264.98 | 2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $140.50 | 2025 | |
| Astellas Pharma US INC | $59.55 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $57.48 | 2025 | |
| Exact Sciences Corporation | $33.68 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $23.80 | 2019 | |
| Pfizer INC. | $23.03 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.14 | 2025 | Jardiance |
| Shield Therapeutics INC | $17.57 | 2025 | |
| Phathom Pharmaceuticals, INC. | $15.75 | 2025 | Voquezna |
| Abbott Laboratories | $15.00 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $13.86 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Bullard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.